GI Innovation and Aimed Bio partner on ‘바카라 전략102’ for glioblastoma clinical research
- Aiming to commercialize 바카라 전략102 combination therapy for relapsed glioblastoma patients - Collaborative research to develop treatment for rare and intractable glioblastoma
[by Ji, Yong Jun] 바카라 전략 Innovation announced on July 22 the signing of a memorandum of understanding (MOU) with Aimed Bio, a company specializing in the development of antibody-drug conjugates (ADCs), to establish a clinical research collaboration focused on glioblastoma multiforme (GBM) treatment.
This MOU aims to pursue ‘Accelerated Approval’ through clinical research on combination therapy involving GI Innovation’s immunotherapy candidate, ‘GI-102 (development code),’ for patients with relapsed GBM who have undergone radiosurgery or other treatments. GI-102 has already demonstrated anticancer activity in preclinical glioblastoma models.
Glioblastoma is a representative malignant tumor of the central nervous system, classified as Grade 4, the highest level of malignancy, under the World Health Organization (WHO) brain tumor classification system, ran바카라 전략ng from Grade 1 to 4. Characterized by a high recurrence rate and mortality, GBM remains a disease with significant unmet needs due to the absence of effective treatment options.
According to the market research firm Global Information, the global GBM treatment market was valued at approximately USD 3.11 billion (approximately KRW 4.35 trillion) in 2023 and is projected to grow to around USD 5.39 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.17%. As one of the most active R&D areas among rare brain tumors, the GBM treatment sector is garnering increasing attention as a potential breakthrough field, driven by the possibility of accelerated development through relatively small-scale clinical trials, 바카라 전략ven the high level of unmet medical need.
Under this collaboration, Aimed Bio will take the lead in 바카라 전략 development, with future commercialization profits to be shared according to a pre-established ratio agreed upon between the two companies. Aimed Bio was founded by Professor Nam Do-hyun of Samsung Medical Center, a leading authority in the field of GBM.
“This agreement is intended to secure ‘conditional approval’ through Phase 2 clinical trials and to facilitate early commercialization,” expressed Jang Myoung-ho, CEO of GI Innovation. “Together with Professor Nam, we will make every effort to establish this new therapy as a global standard treatment for glioblastoma multiforme successful commercialization,” he added.
“We will work together to establish clinical relevance in high-difficulty disease areas such as GBM,” emphasized Her Nam-gu, CEO of Aimed Bio. “This partnership will be a meaningful turning point for both companies.”